Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning

被引:4
作者
Zhan, Min [1 ]
Chen, Zebin [1 ]
Ding, Changcai [2 ]
Qu, Qiang [3 ]
Wang, Guoqiang [1 ]
Liu, Sixi [4 ]
Wen, Feiqiu [4 ]
机构
[1] Shenzhen Childrens Hosp, Dept Pharm, Shenzhen 518036, Peoples R China
[2] Shenzhen Adv Precis Med CO LTD, Dept Res & Dev, Shenzhen 518000, Peoples R China
[3] Xiangya Hosp Cent South Univ, Dept Pharm, Changsha 410008, Peoples R China
[4] Shenzhen Childrens Hosp, Dept Hematol Oncol, Shenzhen 518036, Peoples R China
关键词
Methotrexate clearance; Pediatric hematological malignancies; Pharmacogenomics; SNP genotyping; Machine learning; ACUTE LYMPHOBLASTIC-LEUKEMIA; PLASMA METHOTREXATE; GENETIC-VARIATIONS; ELIMINATION; PHARMACOKINETICS; POLYMORPHISM; TOXICITY; DRUGS; TACROLIMUS; CHILDREN;
D O I
10.1007/s12185-021-03184-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to establish a predictive model to identify children with hematologic malignancy at high risk for delayed clearance of high-dose methotrexate (HD-MTX) based on machine learning. A total of 205 patients were recruited. Five variables (hematocrit, risk classification, dose, SLC19A1 rs2838958, sex) and three variables (SLC19A1 rs2838958, sex, dose) were statistically significant in univariable analysis and, separately, multivariate logistic regression. The data was randomly split into a "training cohort" and a "validation cohort". A nomogram for prediction of delayed HD-MTX clearance was constructed using the three variables in the training dataset and validated in the validation dataset. Five machine learning algorithms (cart classification and regression trees, naive Bayes, support vector machine, random forest, C5.0 decision tree) combined with different resampling methods were used for model building with five or three variables. When developed machine learning models were evaluated in the validation dataset, the C5.0 decision tree combined with the synthetic minority oversampling technique (SMOTE) using five variables had the highest area under the receiver operating characteristic curve (AUC 0.807 [95% CI 0.724-0.889]), a better performance than the nomogram (AUC 0.69 [95% CI 0.594-0.787]). The results support potential clinical application of machine learning for patient risk classification.
引用
收藏
页码:483 / 493
页数:11
相关论文
共 48 条
  • [21] Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia
    Liu, Shu-Guang
    Gao, Chao
    Zhang, Rui-Dong
    Zhao, Xiao-Xi
    Cui, Lei
    Li, Wei-Jing
    Chen, Zhen-Ping
    Yue, Zhi-Xia
    Zhang, Yuan-Yuan
    Wu, Min-Yuan
    Wang, Jian-Xiang
    Li, Zhi-Gang
    Zheng, Hu-Yong
    [J]. ONCOTARGET, 2017, 8 (23) : 37761 - 37772
  • [22] Lopez-Lopez Elixabet, 2013, Pharmacogenet Genomics, V23, P53, DOI 10.1097/FPC.0b013e32835c3b24
  • [23] Explainable machine-learning predictions for the prevention of hypoxaemia during surgery
    Lundberg, Scott M.
    Nair, Bala
    Vavilala, Monica S.
    Horibe, Mayumi
    Eisses, Michael J.
    Adams, Trevor
    Liston, David E.
    Low, Daniel King-Wai
    Newman, Shu-Fang
    Kim, Jerry
    Lee, Su-In
    [J]. NATURE BIOMEDICAL ENGINEERING, 2018, 2 (10): : 749 - 760
  • [24] SLC19A1 transports immunoreactive cyclic dinucleotides
    Luteijn, Rutger D.
    Zaver, Shivam A.
    Gowen, Benjamin G.
    Wyman, Stacia K.
    Garelis, Nick E.
    Onia, Liberty
    McWhirter, Sarah M.
    Katibah, George E.
    Corn, Jacob E.
    Woodward, Joshua J.
    Raulet, David H.
    [J]. NATURE, 2019, 573 (7774) : 434 - +
  • [25] Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients
    Minematsu, T
    Sugiyama, E
    Kusama, M
    Hori, S
    Yamada, Y
    Ohtani, H
    Sawada, Y
    Sato, H
    Takayama, T
    Sugawara, Y
    Makuuchi, M
    Iga, T
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (05) : 1506 - 1511
  • [26] Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters
    Nader, Ahmed
    Zahran, Noran
    Alshammaa, Aya
    Altaweel, Heba
    Kassem, Nancy
    Wilby, Kyle John
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (02) : 221 - 228
  • [27] Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma
    Nakano, Takaaki
    Kobayashi, Ryoji
    Matsushima, Satoru
    Hori, Daiki
    Yanagi, Masato
    Suzuki, Daisuke
    Kobayashi, Kunihiko
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (05) : 744 - 750
  • [28] Review of an Article: The international Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753-64
    Nunnelee, Janice D.
    [J]. JOURNAL OF VASCULAR NURSING, 2009, 27 (04) : 109 - 109
  • [29] Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
    Pui, Ching-Hon
    Carroll, William L.
    Meshinchi, Soheil
    Arceci, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) : 551 - 565
  • [30] Reassessment of the Risk-stratified GD-2008 ALL Protocol
    Que, Li-ping
    Huang, Ke
    Fang, Jian-pei
    Xu, Hong-gui
    Zhou, Dun-hua
    Li, Yang
    Xu, Lv-hong
    Li, Jian
    Chen, Hai-lei
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2018, 40 (06) : 472 - 477